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The cancer stem cell (CSC) concept
goes back a long way. Already in the
19th century the ‘embryonal rest’ theory
proposed that cancers originate from
cells that resemble those from an early
embryo (for a highly recomendable
review and historic overview of the
CSC field; see Nguyen et al, 2012). The
CSC model that eventually emerged from
this has several attractive aspects for the
description and treatment of cancer. By
postulating that tumours harbour a small
subset of cancer stem cells that give rise,
through differentiation and proliferation,
to the bulk of the tumour, as well as new
CSC through self-renewal, the hetero-
geneity of tumours can be explained.
Through parallels with the normal devel-
opment of the corresponding normal cell
types the CSC model can help describe
the earliest steps in the tumourigenic
process before a fully malignant tumour
is formed. Finally it predicts that the
CSC should be the preferred targets of
therapy, but also that due to their stem
cell (-like) state they are often less
responsive to the usual therapies. Much
early work on CSC has been done in
haematopoietic malignancies, maybe not
surprisingly as large parts of their devel-
opmental cascade happens and can be
followed postnatally, followed by a spur
in the identification of CSC from adult
solid tumours in the last 10 years. The
CSC field, however, started with embry-
onal solid tumours (teratocarcinomas;
Nguyen et al, 2012). A paper in this issue
of EMBO Molecular Medicine (Pode-
Shakked et al, 2013) takes the CSC model
back to its embryonic roots by identifying
the Wilms’ tumour CSC.
Wilms’ tumours (WT) have fascinated
pathologists and developmental biolo-
gists alike for a long time. Found in the
kidneys of children usually before the age
of five, they show structures normally
found in developing, embryonic kidneys.
Moreover, a subset of WT shows the
ectopic development of other mesoder-
mal tissues, like muscle, bone, cartilage
and fat. As already noted by Max Wilms
in 1899, this clearly identifies these
tumours as a developmental problem
as much as a tumourigenic one. The
tumours are believed to result from a
disturbance in the mesenchymal-epithe-
lial transition at the onset of nephron
formation and several genome-wide
expression and epigenetic studies have
confirmed the similarity between cells
found in WT and cells at these earliest
stages of nephron development. This
suggests a role for transformed embryo-
nic kidney progenitor cells and CSC in
the origin of these tumours (reviewed in
Pode-Shakked & Dekel, 2011). As many
details about kidney development are
known (Costantini & Kopan, 2010), WT
are an excellent model to study the link
between normal development and tumour-
igenesis through the role of CSC. Yet, the
identity of a WT CSC remained elusive,
partially due to difficulties in propagating
WT samples in xenografts (Xn).
Through an optimized Xn protocol,
Pode-Shakked et al. now identify
NCAMþALDH1þ cells as WT CSC
(Fig 1). Whereas >10,000 unsorted WT
cells need to be injected into immune-
compromised mice for Xn propagation,
only 500 NCAMþ or 200 NCAMþALDH1þ
are required for this. NCAMþ cells show
enrichment in early renal progenitor
markers, stem cell factors and known
poor prognosis factors. Moreover, Xn
samples from NCAMþ cells can recapi-
tulate the complex histology found in
WT, including NCAM descendent cells.
This capability is even maintained after
serial transplantations confirming the
self-renewal capacity of the cells.
Together with other lines of evidence
provided, this clearly identifies the
NCAMþALDH1þ cells as WT CSC. But
most importantly, the authors show that
targeting the NCAMþ population with
cytotoxic drug-conjugated anti-NCAM
antibodies effectively eradicates WT Xn
samples. Not only does this indirectly
further confirm the CSC state of the
NCAMþ cells, it provides a potential
therapeutic approach based on these
findings. Despite the greatly improved
survival of children with WT, patients
that do relapse respond much worse to
subsequent therapy and increasingly later
onset malignancies are found in former
WT patients decades after treatment, likely
to be secondary effects of the original
therapy. The demonstration of success-
fully targeted NCAMþ WT CSC has there-
fore important clinical implications.
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A question that remains open is what
the normal counterpart of the WT CSC is,
and if these normal cells are the cells of
origin of the tumours. Extensive work in
mouse models has revealed that in some
cancers the cell type of origin, the cell
where the initiating mutation has taken
place, is directly transformed into the
CSC, whereas in other types of cancer
the CSC is a transformed descendent of
the cell of origin (Visvader, 2011). The
identification of NCAMþ WT CSC pro-
vides clues about, but does not identify
the cell of origin of these tumours. NCAM
is expressed in the cap-mesenchyme cells
that give rise to the complete nephron,
but not much is known about the NCAMþ
cells found there. Lineage tracing studies
in mice have shown that Six2þ cells in the
cap are the progenitors of the complete
nephron (Kobayashi et al, 2008), and the
WT CSC were found to be enriched for
SIX2 expression. This makes the SIX2þ
cells a good candidate for the normal,
non-transformed counterpart of the WT
CSC, but this has not been formally
proven. As argued by the authors, the
expression of ALDH1 to further define the
WT CSC is likely related to the stem cell
character instead of an indication of the
origin of the tumour.
Tied to this is the question whether the
NCAMþALDH1þ are the CSC of all WT
cases. WT have often been classified in
two classes (Huff, 2011). The smaller
subset is characterized by loss of theWT1
tumour suppressor gene often together
with oncogenic mutations in CTNNB1,
the gene encoding b-catenin, and these
tumours tend to be found associated with
intralobar nephrogenic rests. The major-
ity of WT is wild type for WT1 and
CTNNB1 and are found with perilobar
nephrogenic rests; the initiating mutation
in these tumours is not clear. Clinically
these classes appear different entities
altogether; the WT1-mutant subset of
tumours shows ectopic muscle develop-
ment and has the more favourable
prognosis, whereas the WT1 wild type
subset is developmentally restricted to
renal lineages (though clearly disturbed
in their development) and has the worse
prognosis.
A recent analysis of hundreds of WT
samples confirmed these classes and
extended them to potentially five differ-
ent groups of WT (Gadd et al, 2012). This
extensive dataset suggested a model
where different WT classes originate
from different developmental stages in
the embryonic kidney. How does this
fit with a CSC model? It seems logical
to assume that tumour classes with
different histological appearances would
suggest CSC and/or cells of origin with
different developmental potential. How-
ever, a direct effect of the tumour
initiating mutations (and even subse-
quent mutations and the stage they
occur) on the differentiation potential
of CSC (and therefore the behaviour
of the tumours) cannot be excluded.
All WT CSC described by Pode-Shakked
et al were derived from WT1-wild type
tumours. More analyses will be needed
to determine if the WT1-mutant tumours
also harbour NCAMþALDH1þ CSC.
Furthermore, the genetic aberrations that
drive the WT1-wild type tumours need to
be clarified before their influence on the
NCAMþALDH1þ CSC can be taken into
account.
Eventually, lineage tracing studies in
mice following the fate of different cells
in different mutant backgrounds will be
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Figure 1. The use of small Wilms’ tumour fragments in xenograft experiments greatly improves the
efficiency with which these grafts are formed. Once a xenograft line is established, the efficiency of
propagation further increases per passage and through FACS sorting for NCAMþALDH1þ cells.
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needed to really understand the earliest
steps in WT development. This will likely
have important fundamental implica-
tions for our understanding of kidney
development and tissue commitment in
general. More important for the patients,
at least in the shorter term, is that the
study by Pode-Shakked et al demon-
strates a new approach for the treatment
of the largest and clinically most difficult
class of Wilms’ tumours. The identifica-
tion of the NCAMþALDH1þWT CSC is an
essential step towards a further increase
in (long-term) survival of the patients.
The author declares that he has no
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